Report store
Glioblastoma Multiforme Market Insight, Epidemiology and Market Forecast -2030

Glioblastoma Multiforme Market Insight, Epidemiology and Market Forecast -2030

Published Date : Aug 2021
Pages : 266
Delivery Time : 24 Hours
Region : United States, EU5, Japan

Glioblastoma Multiforme Market

Q: What is Glioblastoma Multiforme?

Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed.

Q: Who are the leading Glioblastoma Multiforme Companies?

The leading Glioblastoma Multiforme Companies include Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others

Q: What are the key strengths of Glioblastoma Multiforme Market Report?

Key strengths of Glioblastoma Multiforme Market Report are 10 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Glioblastoma Multiforme Market Size, Drug Uptake, Pipeline Therapies, Glioblastoma Multiforme Market Drivers and Market Barriers.

Q: Which country is expected to account for the most significant prevalent cases for Glioblastoma Multiforme in the 7MM?

The United States is expected to account for the highest Glioblastoma Multiforme Prevalent Cases.

DelveInsight’s ‘Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glioblastoma Multiforme market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme market size from 2019 to 2032. The report also covers current Glioblastoma Multiforme treatment practice/algorithm, market drivers, market barriers and Glioblastoma Multiforme unmet needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

Glioblastoma Multiforme Market Disease: Understanding and Treatment Algorithm

Glioblastoma Multiforme Overview

Glioblastoma (Glioblastoma Multiforme) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in Glioblastoma Multiforme because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. Glioblastoma Multiformes, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature.

Glioblastoma Multiforme is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. While Glioblastoma Multiforme is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat.

Glioma is considered as the general term which is used to describe the primary brain tumors, and it is also classified to their presumed cell of origin accordingly. The classification includes astrocytic tumors (astrocytoma, anaplastic astrocytoma and glioblastoma), oligodendrogliomas, ependymomas, and mixed gliomas. Gliomas are classified into grade I TO IV on the basis of malignancy that is determined by the histopathalogical criteria. Although the location of Glioblastoma Multiforme is commonly found in the supratentorial region (frontal, temporal, parietal, and occipital lobes), it is rarely located in the cerebellum part. Investigation of genetic and environmental factors of Glioblastoma Multiforme have been done. Prior radiography, decreased susceptibility to allergy, immune factors and immune genes, as well as some nucleotide polymorphisms detected by genomic analysis are all included in the risk factors of the respective disease. The histological classification and tumor grading is a critical step for Glioblastoma Multiforme diagnosis and prognosis.

Glioblastoma Multiforme is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system. Despite multidisciplinary treatments such as surgery, chemotherapy, and radiotherapy, the median survival time for patients with Glioblastoma Multiforme is only 14.6 months. Due to its high degree of invasiveness, radical tumor resection is not curative. From various experimental evidences it is explained that Glioblastoma Multiforme contains a subpopulation of highly tumorigenic cells (Glioblastoma Multiforme stem cells) from which recurrent Glioblastoma Multiforme is thought to derive, and that Glioblastoma Multiforme has the capacity to differentiate into multiple lineages of tumor genesis.

Glioblastoma Multiformes can be classified into primary and secondary Glioblastoma Multiformes:

Primary Glioblastoma Multiforme occurs de novo without evidence of a less malignant precursor
Secondary Glioblastoma Multiforme develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).

Glioblastoma Multiforme Diagnosis

A patient with any neurological symptoms will first be given a physical exam that includes neurologic function tests (reflexes, muscle strength, eye and mouth movement, coordination and alertness). If a tumor is suspected, the patient will have imaging tests so that doctors can look into the brain for any abnormality. A neurological exam alone is not sufficient to make a glioblastoma diagnosis, but the results will indicate whether additional testing is needed. If the results of a neurological exam suggest a potential glioblastoma diagnosis, imaging tests may then be used to produce an in-depth picture of the brain. Procedures that can be used for this purpose include:

Neurological Exams
Angiograms
Magnetic resonance imaging (MRI) and computerized Tomography (CT)
Perfusion MRI
MR spectroscopy
Histological Diagnosis
Surgical Biopsy

Glioblastoma Multiforme Treatment

Treatment for Glioblastoma Multiforme usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since glioblastomas develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient’s brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multispecialty approach can cause several side effects, steroids are often provided as another essential part of glioblastoma treatment, used to help alleviate the side effects of other therapies.

The mainstay of treatment for Glioblastoma is surgery, followed by radiation and chemotherapy. Glioblastoma surgery is performed to achieve a “maximum safe resection,” or removing as much of the tumor as possible without causing lasting neurological damage. Glioblastoma surgery options majorly include: Craniotomy , Awake craniotomy, Debulking surgery, Skull base surgery, Visualase and Kyphoplasty. In most cases, surgeons perform a craniotomy, opening the skull to reach the tumor site. This is done frequently with computer-assisted image-guidance and at times using intra-operative mapping techniques to determine the locations of the motor, sensory and speech/language cortex.

Currently, the first- and second-line treatment of Glioblastoma Multiforme is more prevalent throughout the 7MM. The first-line treatment involves drug therapy following surgery, which includes Temozolomide + Radiation Therapy and Temozolomide Monotherapy. While the second-line treatment for Glioblastoma Multiforme includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant).

Glioblastoma Multiforme Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted Glioblastoma Multiforme Epidemiology Segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme, Gender-specific Diagnosed Incidence of Glioblastoma Multiforme, Type-specific Diagnosed Incidence of Glioblastoma Multiforme, Age-specific Diagnosed Incidence of Glioblastoma Multiforme, Diagnosed Incident Population According To Primary Site Of Glioblastoma Multiforme Tumour and Diagnosed Incident Population According To Histologic Classification of Glioblastoma Multiforme Tumor in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the Glioblastoma Multiforme epidemiology in the 7MM.

The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 29,440 in 2020. In case of Glioblastoma Multiforme patients in the United States, the diagnosed incident cases were 15,426 in 2020.
The total diagnosed incident cases of Glioblastoma Multiforme patients were maximum in males as compared to females in the 7 MM during the study period of 2018–2030.
In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was maximum in Germany with 2,945 cases followed by France with 2,772 cases in 2020. While, Spain accounted for the lowest diagnosed incident population of 1,462 in 2020.
As per Delvelnsight’s analysis, Japan had 1,950 diagnosed incident cases of Glioblastoma Multiforme in 2020.
There were 13,884 patients affected with primary Glioblastoma Multiforme and 1,543 with secondary Glioblastoma Multiforme in 2020, in the United States
The maximum number of the diagnosed incident population in the United States, in 2020, was found at the parietal site with 6,201 cases, followed by frontal tumors with 4,505 cases, temporal tumors with 2,391 cases, 1,620 cases of occipital tumors, and 710 cases of unknown and other tumors.
In 2020, the maximum number of the diagnosed incident population according to the histological classification of Glioblastoma Multiforme were conventional Glioblastoma Multiforme type with 14,964 cases while the lowest incident cases were of GC-Glioblastoma Multiforme type with 123 cases, in the United States.
In the United States, the maximum number of Glioblastoma Multiforme patients lie in the age group of 35–64, which accounted for 10,768 cases in 2020. In contrast, the least number of patients lie in the age group of <18, which was 617 in 2020.

Country Wise- Glioblastoma Multiforme Epidemiology

The epidemiology segment also provides the Glioblastoma Multiforme epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Glioblastoma Multiforme Drug Chapters

The drug chapter segment of the Glioblastoma Multiforme report encloses the detailed analysis of Glioblastoma Multiforme marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Glioblastoma Multiforme clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Glioblastoma Multiforme Marketed Drugs

Avastin: Genentech

Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under “Specialty drugs,” only to be available through specialty pharmacies (under FDA’s Risk Evaluation and Mitigation Strategy (REMS) program).

The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate, wherein no data demonstrate any improvement in disease-related symptoms or increased survival with Avastin.